Moderna’s stock price has doubled following positive results from a key clinical trial of its experimental mRNA cancer treatment. The treatment, currently being tested in melanoma patients, demonstrated a significant reduction in the risk of cancer recurrence or death. Specifically, the trial showed a 44% reduction in risk compared to those receiving standard treatment after surgery. This is the first positive data release from late-stage trials for Moderna’s cancer vaccine program. The results, presented at the American Society of Clinical Oncology annual meeting, have sparked considerable optimism about the potential of mRNA technology beyond COVID-19 vaccines. Further studies are planned to explore the treatment’s efficacy across a broader range of cancers and patient populations. The findings represent a major milestone for Moderna and a potential breakthrough in personalized cancer therapies.